Screener
Charles River Laboratories CRL Manufacturing — Acquisitions
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:GoodwillAcquiredDuringPeriod.
The source filing: Charles River Laboratories’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:21 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001100682-26-000118
| Line item | RMS | DSA (1) | Manufacturing (2) | Total |
|---|---|---|---|---|
| December 27, 2025 | $510,844 | $1,678,518 | $574,891 | $2,764,253 |
| Acquisitions | — | 335,906 | 39,786 | 375,692 |
| Divestitures | — | (37,701) | — | (37,701) |
| Foreign exchange | (551) | (19,320) | (5,522) | (25,393) |
| June 27, 2026 | $510,293 | $1,957,403 | $609,155 | $3,076,851 |
| (1) DSA includes accumulated impairment losses of $1 billion, which were recognized in fiscal years 2008 and 2010. | ||||
| (2) Manufacturing includes accumulated impairment losses of $380 million, which were recognized in fiscal years 2024 and 2025. |
Item 1. Financial Statements
FAQ
- What is Charles River Laboratories's manufacturing — acquisitions?
- Charles River Laboratories (CRL) reported manufacturing — acquisitions of $39.79M in Q2 2026.
- What does manufacturing — acquisitions mean?
- The cash outflow or investment value associated with purchasing other businesses or assets to integrate into the manufacturing segment. This reflects the inorganic growth strategy of the business unit.
Ask your AI about Charles River Laboratories's manufacturing — acquisitions.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude